Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy

SIMPLE SUMMARY: Factors impacting the response to CAR T-cell therapies are not fully understood. In this monocentric prospective study, we describe the outcome of 60 patients with relapsed/refractory diffuse large B-cell lymphoma and transformed follicular lymphoma infused with CD19-directed CAR T-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamure, Sylvain, Van Laethem, François, De Verbizier, Delphine, Lozano, Claire, Gehlkopf, Eve, Tudesq, Jean-Jacques, Serrand, Chris, Benzaoui, Mehdi, Kanouni, Tarik, Quintard, Adeline, De Vos, John, Tchernonog, Emmanuelle, Platon, Laura, Ayrignac, Xavier, Ceballos, Patrice, Sirvent, Anne, François, Mickael, Guedon, Hanane, Quittet, Philippe, Mongellaz, Cedric, Conte, Aurélie, Herbaux, Charles, Bret, Caroline, Taylor, Naomi, Dardalhon, Valérie, Cartron, Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428364/
https://www.ncbi.nlm.nih.gov/pubmed/34503088
http://dx.doi.org/10.3390/cancers13174279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428364/
https://www.ncbi.nlm.nih.gov/pubmed/34503088
http://dx.doi.org/10.3390/cancers13174279

Ejemplares similares